Navigation Links
Novel Therapy for Chronic Problem

Doctors at Mayo Clinic in Rochester, Minn., say they have found a new treatment for a fast-growing disease. Eosinophilic esophagitis (EE) is an allergic inflammatory reaction of the esophagus. The symptoms for EE mimic gastroesophageal reflux disease (GERD). New research shows a topical corticosteroid therapy is effective for patients with EE.
EE is caused by the presence of high levels of eosinophils. Eosinophils are a type of white blood cell that is not normally found in the esophagus and high levels can indicate an allergic response.// EE can make digestion very painful for the patient. Doctors at the Mayo Clinic conducted a study to better understand EE and to determine if the treatment of topical corticosteroids is effective.

The study included 21 patients diagnosed with EE between 1999 and 2001. The patients included 17 men and four women ranging in age from 28 years old to 55 years old. All of the patients were treated with topical corticosteroids for six weeks. The patients swallowed the drug twice a day to coat the esophagus. Interviews were conducted with the patients after treatment and months later.

Researchers say the treatment was effective in all of the patients and lasted a minimum of four months. Researchers also say, though EE mimics the symptoms of GERD, their study found no association between the two disorders. The study concludes EE is a condition that, once diagnosed, can easily and effectively be treated with topical corticosteroid therapy.
'"/>




Page: 1

Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Blood Sugar Kept In Control By Novel Protein
9. Novel antibiotic dressing developed for improved wound healing
10. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
11. Novel drug holds promise for treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... ... Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a new ... not. Yisrayl says with so many titles and names for the Creator, it’s hard ... a little Scripture, backed with a lot of research, the truth is undeniable. , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, a ... its Nova Skin Sciences division, recently announced the launch of Allumière Antiaging Cream, ... power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract and ...
(Date:4/28/2017)... Tenn. (PRWEB) , ... April 28, 2017 , ... ... system, today announced an alliance with B. Braun Medical Inc. , a leader ... role in patient care with as many as 90 percent of hospital patients receiving ...
(Date:4/27/2017)... , ... April 27, 2017 , ... ... natural deodorant. On the heels of Thinksport’s award-winning sunscreen they’ve used the same ... that actually works! , Countless deodorants flood the aisles that contain harmful chemicals ...
(Date:4/27/2017)... ... April 27, 2017 , ... Goodcents Deli Fresh Subs announced ... Lincoln, Neb. area this year. , The first new location will open at ... will open at 84th and Northern Lights Drive this fall. And the third location ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/19/2017)... N.J. , April 19, 2017  Novartis ... by the National Heart, Lung, and Blood Institute ... demonstrating that 58% of patients with treatment-naïve severe ... months when treated with eltrombopag at the initiation ... . The study evaluated three sequential treatment groups, ...
Breaking Medicine Technology: